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Background
It is a class I indication to place AICDs in patients with
ischemic or nonischemic cardiomyopathy with a left
ventricular ejection fraction (LVEF) ≤ 35%. Most com-
monly, the need is determined by LVEF measurements
on 2-D echo. This practice was utilized prior to cardiac
MRI (CMR) establishment as the LVEF “gold standard”
modality. Transthoracic echocardiography is still widely
employed because of its wide availability and perceived
cost savings. This study was designed to compare LVEF
by both 2-D and CMR prior to AICD, along with analy-
sis of comparative Medicare reimbursement.
Methods
Patients in a multi-institutional cardiac imaging database
who underwent AICD implantation according to class I
guidelines were queried for pre-AICD 2-D echo and
CMR exams, constituted the study population. LVEF by
2-D and CMR were assessed for concordance for LVEF
< 35%. The discordant patients were categorized as
higher or lower CMR LVEF, relative to 2-D LVEF.
Using 2012 Medicare reimbursement data for Western
Pennsylvania, imaging reimbursement prior to AICD
implantation per 100 patients was calculated.
Results
131 patients met entry criteria for this study. Seven of
131 patients (5.3%) had LVEF > 35% on CMR, but ≤ 35%
on 2-D. Eleven of 131 patients (8.4%) had LVEF ≤ 35%
on CMR, but > 35% on TTE. Overall, 18 of 131 patients
(13.7%) showed discordance between CMR and 2D and
may have had an incorrect decision for AICD based on
2-D echo alone. The reimbursement of a Structure/Func-
tion CMR exam (codes 75557 and 75565) was $30,653
per 100 patients, while 2-D/Doppler exam (codes 93325
and 93306) was $35,578 per 100 patients.
Conclusions
Of patients undergoing AICD implantation for primary
prevention, 5.3% had an LVEF > 35% on CMR, and may
not have required an AICD. Conversely, 8.4% of patients
would not have received an AICD based on 2-D results.
For patients with cardiomyopathy undergoing assessment
for the need of AICD for primary prevention, CMR is
likely more accurate and is a cost saving imaging strategy
for evaluation of AICD implant candidates with current
reimbursement rates in the United States.
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